In the annual results on record, revenue fell from KRW 27.8 billion in 2022 to KRW 27 billion in 2023 (down 2.9% year on year), then rose to KRW 35.4 billion in 2024 (up 31.2%) and KRW 43.4 billion in 2025 (up 22.4%), growing in two consecutive years. Of the 2022 to 2025 period, 2025 was the largest year.
The company attributed the 2025 gain to steady sales of catalase and lactase, new product launches, and expanded overseas exports. Operating losses of KRW 6.22 billion in 2022 and KRW 9.46 billion in 2023 widened the deficit, before narrowing to KRW 1.88 billion in 2024.
In 2025, operating profit of KRW 1.21 billion marked a turn to profit, with an operating margin of 2.8%. Net income attributable to controlling shareholders was a loss of KRW 18.8 billion in 2024 and a profit of KRW 22.6 billion in 2025.
Net income including non-controlling interests was KRW 22.9 billion in 2025, a different figure from the controlling-shareholder measure. The gap between operating profit and net profit suggests non-operating items had a large effect.
At end-2025, total equity was KRW 54.7 billion, of which KRW 40.9 billion belonged to controlling shareholders, and total liabilities were KRW 81.1 billion. Quarterly results in 2026 have been mixed.
Q4 2025 revenue was KRW 12.5 billion, up 22.6% from the prior quarter, and controlling-shareholder net income was KRW 9.06 billion, but operating loss widened to KRW 655 million. Q1 2026 posted revenue of KRW 11.7 billion and operating profit of KRW 1 billion, but a controlling-shareholder net loss of KRW 2.47 billion.
Q2 2026 revenue was KRW 11.3 billion with operating profit of KRW 983 million and net income of KRW 6.5 billion. Q3 2026 revenue was KRW 11.7 billion with operating profit of KRW 1.42 billion, but a controlling-shareholder net loss of KRW 5.18 billion widened.